JNJ vs NVS
Johnson & Johnson and Novartis AG, both Healthcare
Johnson & Johnson is the larger company at $550B against $281B. On trailing earnings NVS is the cheaper of the two at a P/E of 23.3 against 31.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year JNJ returned +62% against +40% for NVS. Ryufin's sector-relative Smart Score puts JNJ ahead, 9/10 against 8/10.
| Figure | JNJ | NVS |
|---|---|---|
| Last close | $270 | $158 |
| Market cap | $550B | $281B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 31.3 | 23.3 |
| Dividend yield | 1.9% | n/a |
| 1-year return | +62% | +40% |
| 5-year return | +81% | +106% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Johnson & Johnson
Revenue of $25B in Q2 2026, net income $5.5B. Its largest reported line is DARZALEX, 19% of the disclosed total.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or read the correlation.